Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outcome of Radioiodine Treatment in Hyperthyroidism and Predictive Factors of Treatment Failure: A 10-Year Experience
TCTR20220331001Completed
- Sponsor
- Prince of Songkla University
- Start
- Jan 2010
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of iodine-131 in hyperthyroidism, Graves' disease and Hyperfunctioning Multinodular Goiter (MNG), sponsored by Prince of Songkla University. Primary endpoint: Primary treatment outcome. Started Jan 2010; status: completed.
02
Drugs
iodine-131
03
Conditions
hyperthyroidismGraves' diseaseHyperfunctioning Multinodular Goiter (MNG)
Beyond the preview
Go deeper on TCTR20220331001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220331001.